Expression of Leukotriene B4 Receptor 1 Defines Functionally Distinct DCs That Control Allergic Skin Inflammation

By generating Leukotriene B4 (LTB4)-producing enzyme LTA4H knockout mice and CD11c promoter-driven Cre recombinase-expressing BLT1 conditional knockout mice, researchers showed that the migration of BLT1hi dendritic cells exacerbated allergic contact dermatitis.
[Cellular & Molecular Immunology]
Koga, T., Sasaki, F., Saeki, K., Tsuchiya, S., Okuno, T., Ohba, M., Ichiki, T., Iwamoto, S., Uzawa, H., Kitajima, K., Meno, C., Nakamura, E., Tada, N., Fukui, Y., Kikuta, J., Ishii, M., Sugimoto, Y., Nakao, M., & Yokomizo, T. (2020). Expression of leukotriene B 4 receptor 1 defines functionally distinct DCs that control allergic skin inflammation. Cellular & Molecular Immunology, 1–13. https://doi.org/10.1038/s41423-020-00559-7 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Derivatives of Gecko Cathelicidin-Related Antioxidant Peptide Facilitate Skin Wound Healing

Two truncated peptides, Gj-CATH3-(38–42)-peptide and Gj-CATH3-(33–42)-peptide induced HaCaT cell proliferation and prevent decreases in SOD activity and increases of MDA concentration in injured-skin tissue.
[European Journal of Pharmacology]
Derivatives of gecko cathelicidin-related antioxidant peptide facilitate skin wound healing - ScienceDirect. (n.d.). Retrieved October 16, 2020, from https://www.sciencedirect.com/science/article/abs/pii/S001429992030741X?via%3Dihub Cite
Abstract
Bookmark

No account yet? Register

0
Share

Combination of rAd-p53 In Situ Gene Therapy and Anti-PD-1 Antibody Immunotherapy Induced Anti-Tumor Activity in Mouse Syngeneic Urogenital Cancer Models

Researchers undertook a novel combination therapy using rAd-p53 in situ gene therapy and immunotherapy with immune checkpoint inhibitor anti-PD-1 antibody for urogenital cancers. Three mouse syngeneic tumor cell lines, TRAMP-C2 (prostate), MBT-2 (bladder) and Renca (kidney) were used.
[Scientific Reports]
Kunimura, N., Kitagawa, K., Sako, R., Narikiyo, K., Tominaga, S., Bautista, D. S., Xu, W., Fujisawa, M., & Shirakawa, T. (2020). Combination of rAd-p53 in situ gene therapy and anti-PD-1 antibody immunotherapy induced anti-tumor activity in mouse syngeneic urogenital cancer models. Scientific Reports, 10(1), 17464. https://doi.org/10.1038/s41598-020-74660-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share

LncRNA SNHG11 Promotes Gastric Cancer Progression by Activating Wnt/β-Catenin Pathway and Oncogenic Autophagy

Long non-coding RNA small nucleolar host gene 11 (SNHG11) post-transcriptionally upregulated catenin beta 1 and autophagy related 12 through miR-483-3p/miR-1276, while the processing of pre-miR-483/pre-miR-1276 was hindered by SNHG11. SNHG11 induced GSK-3β ubiquitination through interacting with Cullin 4A to further activate the Wnt/β-catenin pathway.
[Molecular Therapy]
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

Dystrophin Dp71ab Is Monoclonally Expressed in Human Satellite Cells and Enhances Proliferation of Myoblast Cells

Dp71ab, but not Dp71, was found to be a molecular enhancer of myoblast proliferation and transfection with Dp71ab may generate a high yield of stem cells for Duchenne muscular dystrophy treatment.
[Scientific Reports]
Farea, M., Rani, A. Q. M., Maeta, K., Nishio, H., & Matsuo, M. (2020). Dystrophin Dp71ab is monoclonally expressed in human satellite cells and enhances proliferation of myoblast cells. Scientific Reports, 10(1), 17123. https://doi.org/10.1038/s41598-020-74157-y Cite
Full Article
Bookmark

No account yet? Register

0
Share

The Hepatic Microenvironment Uniquely Protects Leukemia Cells through Induction of Growth and Survival Pathways Mediated by LIPG

Scientists demonstrated a unique role for liver in modulating the pathogenesis of leukemic disease and suggest that the hepatic microenvironment may protect leukemia cells from chemotherapeutic challenge.
[Cancer Discovery]
The hepatic microenvironment uniquely protects leukemia cells through induction of growth and survival pathways mediated by LIPG | Cancer Discovery. (n.d.). Retrieved October 13, 2020, from https://cancerdiscovery.aacrjournals.org/content/early/2020/10/07/2159-8290.CD-20-0318 Cite
AbstractFull Article
Bookmark

No account yet? Register

0
Share

Tideglusib Attenuates Growth of Neuroblastoma Cancer Stem/Progenitor Cells In Vitro and In Vivo by Specifically Targeting GSK-3β

Investigators evaluated the potential anti-tumor effect of Tideglusib, an irreversible glycogen synthase kinase (GSK)-3β inhibitor drug, on three human neuroblastoma cell lines, SK-N-SH, SH-SY5Y, and IMR-32.
[Pharmacological Reports]
Bahmad, H. F., Chalhoub, R. M., Harati, H., Bou-Gharios, J., Assi, S., Ballout, F., Monzer, A., Msheik, H., Araji, T., Elajami, M. K., Ghanem, P., Chamaa, F., Kadara, H., Abou-Antoun, T., Daoud, G., Fares, Y., & Abou-Kheir, W. (2020). Tideglusib attenuates growth of neuroblastoma cancer stem/progenitor cells in vitro and in vivo by specifically targeting GSK-3β. Pharmacological Reports. https://doi.org/10.1007/s43440-020-00162-7 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Ribonuclease 7-Driven Activation of ROS1 Is a Potential Therapeutic Target in Hepatocellular Carcinoma

Oncogenic function of RNase7 was analyzed by cell proliferation, migration, invasion assays and xenograft mouse model. The anti-ROS1 inhibitor treatment efficacy was evaluated in hepatocellular carcinoma patient-derived xenograft and orthotopic models.
[Journal of Hepatology]
Liu, C., Zha, Z., Zhou, C., Chen, Y., Xia, W., Wang, Y.-N., Lee, H.-H., Yin, Y., Yan, M., Chang, C.-W., Chan, L.-C., Qiu, Y., Li, H., Li, C.-W., Hsu, J.-M., Hsu, J. L., Wang, S.-C., Ren, N., & Hung, M.-C. (2020). Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma. Journal of Hepatology, 0(0). https://doi.org/10.1016/j.jhep.2020.09.030 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

CD19-Specific CAR-T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor is Effective in Patients with PD-L1 Positive B-Cell Lymphoma

Scientists generated a novel anti-CD19 CAR expressing PD-1/CD28 chimeric switch-receptor. They then conducted a Phase Ib study to evaluate safety and efficacy of CD19-PD-1/CD28-CAR T cells in the treatment of PD-L1+ B-cell lymphoma.
[Clinical Cancer Research]
Liu, H., Lei, W., Zhang, C., Yang, C., Wei, J., Guo, Q., Guo, X., Chen, Z., Lu, Y., Young, K. H., Lu, Z., & Qian, W. (2020). CD19-Specific CAR-T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor is Effective in Patients with PD-L1 Positive B-Cell Lymphoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-20-1457 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Polydeoxyribonucleotide-Delivering Therapeutic Hydrogel for Diabetic Wound Healing

In vitro studies using human dermal fibroblasts and diabetes mellitus fibroblasts and an in ovo chorioallantoic membrane assay confirmed that the Alg-PDRN hydrogel effectively induced cell proliferation and expression of angiogenic growth factors and promoted new blood vessel formation.
[Scientific Reports]
Shin, D. Y., Park, J.-U., Choi, M.-H., Kim, S., Kim, H.-E., & Jeong, S.-H. (2020). Polydeoxyribonucleotide-delivering therapeutic hydrogel for diabetic wound healing. Scientific Reports, 10(1), 16811. https://doi.org/10.1038/s41598-020-74004-0 Cite
Full Article
Bookmark

No account yet? Register

0
Share

ROCK Inhibitor Combined With Ca2+

Investigators showed that the combination of Rho-associated kinase (ROCK) inhibition with Ca2+ elevation regulated the phosphorylation of myosin light chain II and improved both cell expansion and cell–cell adhesion during the culture of human nasal mucosal epithelial cell sheets.
[Scientific Reports]
ROCK inhibitor combined with Ca 2+ controls the myosin II activation and optimizes human nasal epithelial cell sheets | Scientific Reports. (n.d.). Retrieved October 8, 2020, from https://www.nature.com/articles/s41598-020-73817-3 Cite
Full Article
Bookmark

No account yet? Register

0
Share
Share